Nasal administration of T (4.5% testosterone nasal gel, Natesto) allows for rapid absorption through the nasal mucosa such that serum T levels reach a peak concentration in ∼40 min.
Acerus is a Canadian-based pharmaceutical company focused on the commercialization and development of innovative pharmaceutical products that improve the patient experience.
Founded in 2008, Acerus has grown into a fully integrated specialty pharmaceutical company with expertise in all stages of the pharmaceutical product life-cycle. The company is focused on Men’s Health (Urology and Andrology).
Acerus’ foundational product Is NATESTO®, a testosterone therapy based on our patented nasal gel technology. NATESTO® is approved in the United States, Canada, and South Korea for the treatment of adult males diagnosed with hypogonadism.
Acerus operates from a Mississauga-based office and is listed on the Toronto Stock Exchange (TSX: ASP) and the OTCQB Exchange (OTCQB: ASPCF).
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.